Emerging efficacy data have led to the emergency use authorization or approval of COVID-
19 vaccines in several countries worldwide. Most trials of COVID-19 vaccines excluded …

Multiple myeloma (MM) is a hematologic malignancy defined by the clonal proliferation of
transformed plasma cells. Despite tremendous advances in the treatment paradigm of MM, a …

Background Patients with hematological malignancies (HM) are at high risk of mortality from
SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse …

Patients with cancer have high mortality from coronavirus disease 2019 (COVID-19), and the
immune parameters that dictate clinical outcomes remain unknown. In a cohort of 100 …

Background Haematological malignancies and their treatments are likely to affect SARS-
CoV-2 vaccine efficacy. We aimed to evaluate serological response to BNT162b2 vaccine in …

Background Patients with cancer may be at high risk of adverse outcomes from severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of …

Importance COVID-19 is a life-threatening illness for many patients. Prior studies have
established hematologic cancers as a risk factor associated with particularly poor outcomes …

Background Safety and immunogenicity of BNT162b2 mRNA vaccine are unknown in
hematological patients; both were evaluated prospectively in 42 patients with multiple …

Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients
with hematological malignancies. Neutralizing antibodies (NAbs) against SARS-CoV-2 were …

Patients with multiple myeloma (MM) are at an increased risk for infection because of their
immunocompromised state, old age, and comorbidities. 1 Coronavirus disease 2019 …